Every 424B that DAXOR CORP (DXR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow DXR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DXR filings page.
Daxor Corporation is conducting a registered direct offering of 765,958 shares of common stock at $11.75 per share, for a stated gross offering size of $9,000,006. After paying an 8.0% placement fee to Lake Street Capital Markets and estimated offering expenses, Daxor expects net proceeds of about $8.14 million.
The company plans to use the cash for working capital and general corporate purposes, including product development, capital expenditures, potential investments or acquisitions, and repayment of some outstanding borrowings, with any unused funds temporarily invested in investment‑grade preferred stocks. As of January 22, 2026, Daxor had 5,061,267 common shares outstanding, a market price of $13.70 per share, and a net asset value of $6.98 per share, meaning the stock traded at a substantial premium to NAV. Daxor is registered as a closed‑end investment company but intends to seek an order under Section 8(f) of the Investment Company Act to cease being a registered investment company, which would remove Investment Company Act protections if granted.
Daxor Corporation, a Nasdaq-listed medical instrumentation and biotechnology company that is registered as a closed-end investment company, plans a registered direct offering of common stock to institutional investors through Lake Street Capital Markets as placement agent. The company notes that, under SEC rules for smaller issuers, the aggregate market value of securities it may offer in any 12‑month period under this shelf is limited to one third of its public float, and cites a current capacity figure based on recent trading prices. Daxor intends to use net proceeds for working capital and general corporate purposes, including product development, capital expenditures, potential investments or acquisitions, and repayment of borrowings, with interim investment in investment‑grade preferred stocks. The company also states that it plans to apply under Section 8(f) of the Investment Company Act for an order declaring it has ceased to be a registered investment company, which would remove Investment Company Act protections if granted, while its shares remain listed on Nasdaq under the symbol DXR.
Daxor Corporation has filed a base prospectus to offer up to $25,000,000 of its common stock from time to time and to register shares for resale by the Joseph Feldschuh Estate. The company may sell shares directly, through agents or underwriters, with specific terms and pricing to be detailed in future prospectus supplements. Net proceeds from primary sales are expected to support working capital, product development, capital expenditures, potential investments or acquisitions, and debt repayment, with unused funds invested in investment-grade preferred securities.
The prospectus also registers common stock held by the Joseph Feldschuh Estate, which controls more than 50% of Daxor’s voting power; all proceeds from those resales will go to the selling shareholder, not the company. Daxor operates its BVA-100 blood volume analyzer and Volumex diagnostic kit from its Oak Ridge, Tennessee facility and relies heavily on an investment portfolio concentrated in electric utility stocks. The company intends to seek deregistration as a closed-end investment company, which would remove Investment Company Act protections for investors and could change its tax treatment; if that order is granted, offerings under this document would cease and be shifted to a different registration format.